Pharmacology
Mechanism of Action
Bisphosphonate; inhibits bone resorption via actions on osteoclast activity, leading to indirect increase in bone density
Absorption
Onset: Hypercalcemia of malignancy, 4-7 days; osteolytic bone metastases, 1 week
Duration: 32 days
Distribution
Protein bound: 28-53%
Metabolism
Not metabolized
Elimination
Half-life: 146 hr (terminal)
Renal clearance: 66 mL/min
Total body clearance: 5.6 L/hr
Excretion: Urine (39% as unchanged drug) within 24 hr, feces (<3%)
Administration
IV Incompatibilities
Calcium-containing solutions
IV Preparation
Reconstitute powder with 5 mL SWI; once powder is fully dissolved, dilute further in 100 mL NS or D5W before administering
Infusion of solution must be completed within 24 hours of initial reconstitution
IV Administration
Infuse over ≥15 minutes, in line separate from other medications
Ensure appropriate hydration, especially in patients on diuretics
Storage
Before dilution, store vials at 25°C (77°F); after final dilution, use solution immediately or store at 2-8°C (36-46°F)
Pack Size:
1’S
Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions.
Read moreColorectal cancer is a major cause of morbidity and mortality, being one of the most common malignant tumors in the world.
Read moreCancer of the prostate is the most common malignancy in elderly men
Read moreChemotherapy-induced neutropenia is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality, and can increase the overall cost of providing cancer therapy.
Read moreSome types of cancer may cause bone damage leading to high levels of blood calcium and lesions that cause severe bone pain, bone masses & fractures.
Read more